Indogulf's Barwasni plant delayed a year. Sudan also missed.
The ₹1,000-cr revenue target is now a two-to-three-year bet. A key capacity expansion has slipped into FY27.
— 2 earlier stories on Indogulf Cropsciences Ltd. →What's new
- Barwasni plant commissioning delayed to H2 FY27 from Q4 FY26 due to Delhi-NCR environmental stoppages.
- Sudan market entry missed earlier timeline; biostimulant launch in Sri Lanka succeeded.
- Revenue target of ₹1,000 cr reiterated, to be achieved within two to three years.
Why this matters
The results themselves are solid, but the concall was about what isn't working. Two international expansion moves have slipped, and the key domestic capacity build is now a year late. That pushes the ₹1,000-cr ambition further out.
What we're watching
- H1 FY27 progress on Barwasni regulatory clearances and construction.
- Clarity on the revised Sudan entry timeline.
- Margin impact as the product mix shifts toward biologicals.
The full read
Indogulf Cropsciences closed FY26 with a 27% jump in net profit to ₹40 crore on 19% higher revenue of ₹705 crore. That's the good news. The concall revealed the less good: the Barwasni facility expansion, originally due this quarter, is now delayed to H2 FY27 after environmental stoppages in Delhi-NCR. The planned Sudan market entry has also missed its timeline. Management is sticking to its ₹1,000 crore revenue target, but now frames it as a two-to-three-year goal. That timeline sits awkwardly against the delayed capex. The ₹86 crore spent so far is ample for the next three to four years, the company says. The open question is whether the delayed Barwasni plant still underpins that growth ambition or just delays it.
Questions answered
- Why was the Barwasni plant delayed?
- Environmental regulatory stoppages in the Delhi-NCR region halted the project, pushing its commissioning from Q4 FY26 to the second half of FY27.
- What is the updated revenue target?
- Management reiterated a target of ₹1,000 crore-plus within two to three years, backed by ₹86 crore in capex they say is sufficient for the next three to four years.
- How did the financials look?
- FY26 revenue rose 19% to ₹705 crore and net profit grew 27% to ₹40 crore, driven by a shift toward higher-margin biological products.
- Which export market worked?
- The company succeeded in Sri Lanka with its biostimulant products. Its entry into Sudan, however, has missed the earlier planned timeline.
Story so far
All notes on IGCL →- 29 May 2026 · 1:51 PM IST Indogulf's Barwasni plant delayed a year. Sudan also missed.
- 1d ago Indogulf Cropsciences reports ₹40 cr profit for FY26
- 1d ago Indogulf Cropsciences reissues audited FY26 results